Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

d special and acquisition-related charges

(f) Included in cumulative effect in change in accounting principle, net

SCHERING-PLOUGH CORPORATION

Report for the period ended December 31 (unaudited):

GAAP Net Sales by Key Product

(Dollars in millions) Fourth Quarter Full Year

2007 2006 % 2007 2006 %

GLOBAL

PHARMACEUTICALS a/ $2,963 $2,211 34% $10,173 $8,561 19%

REMICADE 455 337 35% 1,648 1,240 33%

NASONEX 271 253 7% 1,092 944 16%

PEGINTRON 239 208 15% 911 837 9%

TEMODAR 234 189 23% 861 703 22%

CLARINEX /

AERIUS 174 164 6% 799 722 11%

CLARITIN RX 93 78 19% 391 356 10%

AVELOX 115 103 12% 384 304 26%

INTEGRILIN 91 85 7% 332 329 1%

REBETOL 71 75 (6%) 277 311 (11%)

CAELYX 66 49 33% 257 206 25%

INTRON A 57 57 - 233 237 (2%)

SUBUTEX /

SUBOXONE 57 51 11% 220 203 8%

PROVENTIL /

ALBUTEROL CFC 41 55 (25%) 207 203 2%

ASMANEX 41 36 16% 162 103 57%

ELOCON 37 33 10% 156 141 11%

FORADIL 25 28 (11%) 102 94 8%

NOXAFIL 29 10 N/M 89 19 N/M

FOLLISTIM c/ 57 - N/M 57 - N/M

NUVARING c/ 45 - N/M 45 - N/M

<
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... is about to emerge in the world of pesticides and ... to understand the implications for public health, ensure that this ... risks, researchers say in a new report. In a ... and Environmental Health , scientists from Oregon State University and ...
... Oct. 4 Amgen (Nasdaq: AMGN ) ... ,181, pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in ... and second-line treatment for metastatic colorectal cancer (mCRC), respectively, ... Oncology . "Both studies demonstrated that ...
... NEW YORK, Oct. 4 Reportlinker.com announces that ... its catalogue: Global Soft Tissue ... This report analyzes the worldwide markets ... the following segments: Cartilage Allografts, Meniscus Allografts, and ...
Cached Biology Technology:New approaches needed to gauge safety of nanotech-based pesticides 2New approaches needed to gauge safety of nanotech-based pesticides 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , January 22, 2015 , ... tenth year  The European Patent Office to present a ... Two British nominations to be featured: Christofer Toumazou and ... featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... called ribonucleotides become embedded in genomic DNA, which contains ... cause problems for cells. It is known that ribonucleotides ... resulting in genomic instability and altered DNA metabolism, but ... ribonucleotides. A new study provides a mechanistic explanation ...
... and colleagues have produced the most comprehensive mathematical model ... to environmental change. The research, federally ... 2 in the journal Science . ... unites various sub-disciplines of population biology, including population ecology, ...
... Los Angeles, CA (December 2nd, 2011) Most of ... new results out in the journal Clinical Rehabilitation , ... to reduce early retirement on health grounds in Finland had ... evaluative study of vocational rehabilitation, which followed 872 participants and ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
Mycoplasma tested...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
...
Request Info...
Biology Products: